Spiramycin tablets 1.5M IU for congenital toxoplasmosis (Sanofi, toxoplasmosis, gondii, Rovamycin)

General information on Japanese Spiramycin tablets 1.5M IU for congenital toxoplasmosis (Sanofi, toxoplasmosis, gondii, Rovamycin)

Package details: 96 tablets

Manufacturer: Sanofi K. K., Japan

Active ingredient: spiramycin (chemical formula C43H74N2O14)

Medical effect: Spiramycin tablets are effective for suppressing the onset of congenital toxoplasmosis in pregnant women.

Contraindications and precautions: do not use for breastfeeding women.

If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration of Spiramycin tablets 1.5M IU from Japan for congenital toxoplasmosis (Sanofi, toxoplasmosis, gondii, Rovamycin)

For pregnant women: take 2 tablets (3millions of IU of the active ingredient) at a time, 3 times a day.

How effective are Spiramycin tablets 1.5M IU from Japan for congenital toxoplasmosis (Sanofi, toxoplasmosis, gondii, Rovamycin)?

Spiramycin is a macrolide antibiotic and antiparasitic. It works by inhibit protein synthesis in cells of bacteria and parasites. Spiramycin is effective against the following:

• Gram-positive cocci and rods,
• Gram-negative cocci,
• Legionellae,
• mycoplasmas,
• chlamydiae,
• some types of spirochetes,
• Cryptosporidium species,
• Toxoplasma gondii.

Who should take Spiramycin tablets 1.5M IU from Japan?

Spiramycin tablets are used for suppressing the onset of congenital toxoplasmosis in pregnant women. This medicine does not only fight Toxoplasma gondii but also prevents placental transmission of toxoplasmosis, significantly decreasing the chance that the unborn baby will get the infection. Studies showed that up to 94% of expecting mothers with acute toxoplasmosis who received the treatment with spiramycin have no toxoplasma in the amniotic fluid (Muhittin Eftal Avci, Ferhat Arslan et al. “Role of spiramycin in prevention of fetal toxoplasmosis”. Journal of Maternal-Fetal and Neonatal Medicine, 2016; 29(13): 2073-6).